Former Immunocore and GSK researcher named Zelluna CSO

13 August 2018
zelluna_namir_hassan_large

Namir Hassan has been named chief scientific officer of Zelluna Immunotherapy, a privately-held Norwegian biotech specializing in T-cell receptor (TCR) immunotherapies.

Dr Hassan joins from UK-based Immunocore, where he was praised for building and growing the biology, preclinical and biomarker units targeting oncology, and oversaw early development and the first-in-human trial of a TCR based biologic targeting a melanoma antigen, gp100. He has also worked at pharma major GlaxoSmithKline (LSE: GSK) and at the Ludwig Institute for Cancer Research.

"I joined Zelluna because I believe these TCRs provide opportunities for driving differentiated therapeutic benefits in patients fighting solid cancers"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology